OMED Health Plans launched by Owlstone Medical for gastrointestinal conditions

OMED Health, a division of breath biopsy company Owlstone Medical, has launched OMED Health Plans, a range of personalised treatments and services to help patients gain control of their functional gastrointestinal (GI) conditions, a problem affecting one billion people worldwide.

The plans include the diagnosis of small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) through at-home breath testing and substrate tests using the OMED Health Breath Analyser.

Initially the plans will be made available through healthcare providers as part of a push to support three goals: moving care from hospitals to communities, developing clinician-led care pathways including nutritional protocols such as FODMAP and therapeutic interventions, and encouraging one-to-one clinical consultation for expert support.

“Owlstone is building a category-defining platform through OMED Health at the intersection of diagnostics, digital health, therapeutics, and personalised care,” said Billy Boyle, CEO and co-founder of Owlstone Medical

“Digestive health is one of the largest untapped opportunities in consumer-facing diagnostics and chronic disease management.

“Through the expanded OMED offering, patients with functional GI conditions will for the first time be able to access end-to-end, clinician-led, and evidence-based treatment plans utilising longitudinal breath monitoring, optimised specifically for them based on their breath profiles.”